QCM Cayman’s Context Therapeutics CNTX Stock Holding History

QCM Cayman’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-14,041	Closed	-$37K	–	100
2021 Q4	$37K	Buy	+14,041	New	+$70K	0.22%	63

Other funds holding CNTX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QCM Cayman's CNTX Position: Q1 2022 in Review

QCM Cayman sold out of Context Therapeutics (CNTX) in Q1 2022, closing a stake of 14,041 shares — an estimated $37K sold.

QCM Cayman first reported a position in CNTX in Q4 2021 and held it in 1 quarter. The position peaked at $37K in Q4 2021. 16 funds tracked by Wall St. Rank hold CNTX as of Q1 2022.

QCM Cayman reported no remaining Context Therapeutics position as of Q1 2022 after selling out during the quarter.
QCM Cayman sold 14,041 Context Therapeutics shares in Q1 2022, an estimated $37K.
QCM Cayman first reported a position in Context Therapeutics in Q4 2021 and held it in 1 quarter.
QCM Cayman's Context Therapeutics position peaked at $37K in Q4 2021.
16 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2022.

Based on QCM Cayman's 13F filing for Q1 2022, filed 6 May 2022.